On the profitability of strategic research networks: a simulation model for pharmaceuticals Online publication date: Wed, 05-Mar-2014
by Kalevi Kyläheiko; Pasi Luukka; Ari Jantunen
International Journal of Technology Intelligence and Planning (IJTIP), Vol. 9, No. 3, 2013
Abstract: This paper analyses the profitability of research networks in the pharmaceutical industry where R&D-based activities are of great importance for the companies following the offensive research strategy, i.e., generating original drugs. There are also companies who follow the defensive strategy, i.e., develop generic drugs. We focus on the issue how knowledge-related capabilities can be utilised when trying to profit from innovations. The larger the knowledge pool to be used by the companies, the higher is the probability to profit from new innovation. This is one of the greatest motivations to establish strategic research networks. However, the more innovative the offensive companies are the more opportunities there are also for defensive companies. We tackle this innovation race by a simulation model that scrutinises the profitability of research networks in the three company world where tacitness, legal appropriability means, and absorptive capacities are used as means of technology strategies.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Intelligence and Planning (IJTIP):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook